Moreover, high prevalence of
chronic pain diseases is expected to foster the growth of Phenylalanine
Market over the forecast period. For instance, according to the American
Academy of Pain Medicine (AAPM), in 2011, around 1.8 billion people suffered
from chronic pain. Moreover, the National Institutes of Health (NIH) estimates
that one in 10 people in the U.S. suffer from chronic pain. According to a
study published in the British Medical Journal in 2016, nearly one-third to
half of the population in the U.K. suffers from chronic pain. Moreover,
according to the NIH estimates published in 2015 by the American Pain Society,
around 50 million people in the U.S. suffered from chronic pain.
Phenylalanine is essential alpha
amino acid, which functions to maintain adequate levels of monoamine
neurotransmitters in the brain, thereby maintaining balanced moods. Deficiency
of phenylalanine causes mental confusion, depression, reduced alertness, memory
impairment, and loss of appetite. Phenylalanine is majorly present in three
forms: D-Phenylalanine, DL-Phenylalanine, and L-Phenylalanine. L-phenylalanine
is natural amino acid found in the proteins, while D-Phenylalanine is
synthesized form of phenylalanine, produced in laboratory. DL-phenylalanine is
synthetic product made of 50% D-phenylalanine and 50% of L-phenylalanine.
L-phenylalanine is an essential
amino acid, which is also an only form of phenylalanine found in proteins.
Major dietary sources of L-phenylalanine include meat, fish, eggs, cheese, and
milk. L-phenylalanine and DL-phenylalanine are commonly used to treat
depression, Attention Deficit-Hyperactivity Disorder (ADHD), chronic pain, and a
skin disease called vitiligo.
The primary function of
phenylalanine is to produce tyrosine, which further gets converted into three
key neurotransmitters: L-dopa, norepinephrine, and epinephrine. As some
antidepressants function by increasing levels of norepinephrine, various forms
of phenylalanine have been observed as a possible treatment for depression.
Furthermore, D-phenylalanine has been found to be effective in the treatment of
chronic pain. It blocks enkephalinase, an enzyme which increases pain levels in
the body.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1828
Phenylalanine Market Drivers
Increasing prevalence of anxiety
and depression are responsible for massive consumptions of anti-depressants, in
turn promoting global phenylalanine market growth. For instance, according to
the World Health Organization (WHO) data findings, in 2017, over 300 million
people of all ages are suffering from depression worldwide, wherein around
800,000 people die due to suicide due to anxiety disorders and depression as
prime cause. Moreover, according to the National Institute of Mental Health
(NIMH), in 2016, an estimated 10.3 million U.S. adults (4.3% of all U.S.
adults) aged 18 or older had at least one major depressive episode with severe
impairment. Furthermore, according to the same source, the prevalence of major
depressive cases was higher among adult females (8.5%) as compared to males
(4.8%). Furthermore, the prevalence of adults with a major depressive episode
was highest among individuals aged 18-25 (10.9%). The association (NIMH) also
mentions that these disorders are highly treatable thereby propelling
opportunities for growth of the global phenylalanine market.
Furthermore, increasing
prevalence of pain and chronic diseases such as cancer and others are driving
growth of the phenylalanine market. For instance, according to the National
Cancer Institute, in 2018, around 1,735,350 new cases of cancer are expected to
be diagnosed in the U.S. and 609,640 people are expected to die from the
disease.
Phenylalanine Market Restraints
Phenylalanine should be avoided
in people with certain inherited disorders such as Phenylketonuria (PKU), where
body build up too much phenylalanine. People with phenylketonuria can develop
mental retardation, high blood pressure, stroke, and many other serious health
issues if they consume phenylalanine. PKU is severe disorder due to which
infants are generally screened at birth to determine whether they have the
disorder and will need a special diet to avoid these problems.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/phenylalanine-market-1828
Phenylalanine Market – Regional
Analysis
Geographically, the global
phenylalanine market is segmented into North America, Latin America, Europe,
Middle East, Asia Pacific, and Africa. Increasing incidence of cancer and
rising number of trauma cases worldwide is propelling demand for pain
management associated with it. North America phenylalanine market is expected
to witness significant growth during the forecast period. As per statistics
published by Centers for Disease Control and Prevention (CDC), in 2014, trauma
accounts for 41 million visits to the emergency ward each year in the U.S.
Furthermore, developed economies
such as the U.S., U.K. and Germany experience high rate of adoption due to
better healthcare facilities and easy availability of depression medication in
these countries. According to the American academy of pain medicine, every
year, over 100 million people suffer from chronic pain, 25.8 million from diabetes,
16.3 million from coronary heart disease, and 11.9 million from cancer in the
U.S. This number is expected to further increase in the near future.
Increasing research and
development initiatives by various government and non-governmental organizations
such as National Institutes of Health (NIH) Brain Research through Advancing
Innovative Neurotechnologies (BRAIN), which aims to better understand the human
brain and harness the same for various therapeutic applications, including
effective pain management, is expected to create a conducive environment for
market growth in these region.
Phenylalanine Market – Competitor
Some of the key players operating
in the phenylalanine market include Amazing Nutrition, LiftMode (Synaptent
LLC), NutraMarks, Inc., NOW foods, healthvit, and Shijiazhuang Jirong
Pharmaceutical Co., Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1828
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment